HUMA Humacyte Inc

$HUMA "Our commercial execution is generating strong momentum across the United States and validating the significant unmet need for an off-the-shelf bioengineered vascular conduit," said Jim Mercadante, Chief Commercial Officer of Humacyte. "

$HUMA Mr. Mercadante added, “We are encouraged by the accelerating commercial momentum for Symvess and look forward to providing further perspective on hospital adoption, surgeon engagement, and our growth opportunities during our Q3 earnings call.” Mercadante is already laying the ground work for the Q3 earnings call and might be the best thing to happen to company this year other than the v012 results. I am encouraged.

$HUMA bought 15k more shares at 40 cents. Now at 325k shares .77 cent average. Never thought I’d be able to buy at these levels. The last stock I had did the same thing and it went from $.40 to 2.40 Patience is a virtue

$HUMA this stock has more than paid the market price for its poor finanical and managerial performance. At this point its being artificially supressed for reasons that have not become clear yet. Its basic assests i.e. factories, patented IP, etc, is worth more than the currently assesed value. Companies continue to invest (buy its stock) and lending institutions continue to lend money. Those are not "hope" based investors. Would love to know what is really going on...

$HUMA bears say it’s so over but the price says things are ramping up. Looks like people are figuring out that exceeding hospital enrollment is a close proxy for exceeding sales.

$HUMA Bought 15k more shares! Another great dip from yesterday! Time to load up! 400k shares now .69 cent cost average

$HUMA things are finally looking encouraging. Just happy i didnt sell and and kept buying at throught the drop. When this grows i will be laughing

$HUMA **HUMA — new Symvess patent, protection into 2043** Humacyte announced today the issuance of U.S. Patent No. 12,742,144, covering how Symvess (ATEV) and other bioengineered tissues are manufactured, sterilized, stored, and shipped — extending platform IP protection into 2043. Caveat, not a readout: this does not expand Symvess's approved uses and is not a clinical or regulatory result. It sits ahead of the November sBLA filing already pinned, as IP cover for the product's logistics chain. Source:

$HUMA it will be huge at some point. Nobody in management seems very concerned. There’s a reason for that. It’s because when it happens, it’ll happen. $40+

$HUMA DATA is amazing and deserves a dollar fifty we already saw it once now maybe they'll package it to show how big the total addressable Market is then the sbla and device one is showing a great uptake Market will re-rate this sooner or later

$HUMA I need to start buying a position again. Too bad the management is trash but the tech is incredible.

$HUMA im praying 🙏 this is the BOTTOM & WE shoot up from here. I have a massive position and believe TAM IN DIALYSIS is 100 times bigger market for HUMA with incredible data & KOL'S expert opinions. Women & obese patients make up more than 50% of patients the SBLA is targeting

Prepare to launch $HUMA with their sBLA submission coming soon. Could be November 1st? The FDA should approve that quickly too. This train is about to leave the station.

$HUMA Humacyte Stops Phase 3 Dialysis Vessel Trial Early After Meeting Main Efficacy Goal Humacyte reported positive interim Phase 3 data from its V012 trial of the acellular tissue engineered vessel in female hemodialysis patients, with the product meeting the primary efficacy endpoint and enrollment stopped early after showing functional vascular access more than three months earlier than standard arteriovenous fistulas and more catheter-free days in the first year. The early stop for efficacy in this late-stage study points to meaningful clinical benefit in a group that often sees challenges with vascular access, which could be important for how regulators and clinicians view Humacyte’s platform across other dialysis and vascular surgery uses.

$HUMA Surgeons and hospitals are risk adverse and very much going to protect their reputations. As Humacyte onboards more surgeons, expect adoption to increase exponentially. These photos are way more important than I think anyone really recognizes aside from Mercadante.

$HUMA take my advice i bought precigen at 80 cents and now its at 7.30 a share. this is another precigen believe me. it might take a while but its on the same path going forward

$HUMA the buy of a lifetime in the 40 cent. fook day trading just load up and in 2 years your going to be a millionaire ten times over

$HUMA im telling every investor here reguarding humacyte. at these levels im saying buy the shiit out of this stock and as long as it stays at these levels just buy buy buy and buy more because im saying eventually revenues are going to rise and rise and rise. this will be eventually a 2 billion dollar market cap and probably alot more. so load up at these prices while you can because i am bigtime

$HUMA any of you long term bag holders better pray this gets pumped up enough to cut your losses at 50% instead of 90% 😭 speaking for a friend

$HUMA would meet all the requirements for a second 180-day extension to get above $1.00. Furthermore, the unwritten rule generally followed by small-cap companies is to leverage both the initial 180-day period and the 180-day extension to the very last available day before actually executing a reverse stock split. Additionally, if the sBLA for dialysis is filed in November with a Priority Review request (as it should, according to the previous communication), the existing cash runway should be sufficient to cover operating expenses until potential FDA approval (End of Q2 2027).